BG60256B2 - Рекомбинантен метод за получаване на лимфотоксин - Google Patents

Рекомбинантен метод за получаване на лимфотоксин Download PDF

Info

Publication number
BG60256B2
BG60256B2 BG70460A BG7046085A BG60256B2 BG 60256 B2 BG60256 B2 BG 60256B2 BG 70460 A BG70460 A BG 70460A BG 7046085 A BG7046085 A BG 7046085A BG 60256 B2 BG60256 B2 BG 60256B2
Authority
BG
Bulgaria
Prior art keywords
lymphotoxin
dna
sequence
amino acid
nucleic acid
Prior art date
Application number
BG70460A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG60256B1 (bg
Inventor
Bharat Aggarwal
Timothy BRINGMAN
Patrick Gray
Glenn Nedwin
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/616,502 external-priority patent/US4959457A/en
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of BG60256B1 publication Critical patent/BG60256B1/bg
Publication of BG60256B2 publication Critical patent/BG60256B2/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C07K16/242—Lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C07K14/5255—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BG70460A 1984-05-31 1985-05-30 Рекомбинантен метод за получаване на лимфотоксин BG60256B2 (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61650384A 1984-05-31 1984-05-31
US06/616,502 US4959457A (en) 1984-05-31 1984-05-31 Anti-lymphotoxin
US73231285A 1985-05-09 1985-05-09

Publications (2)

Publication Number Publication Date
BG60256B1 BG60256B1 (bg) 1994-03-24
BG60256B2 true BG60256B2 (bg) 1994-03-24

Family

ID=27417179

Family Applications (1)

Application Number Title Priority Date Filing Date
BG70460A BG60256B2 (bg) 1984-05-31 1985-05-30 Рекомбинантен метод за получаване на лимфотоксин

Country Status (23)

Country Link
EP (2) EP0164965B1 (index.php)
JP (3) JP2521703B2 (index.php)
AR (1) AR245219A1 (index.php)
AT (2) ATE195323T1 (index.php)
AU (1) AU599303B2 (index.php)
BG (1) BG60256B2 (index.php)
CA (1) CA1340641C (index.php)
CZ (1) CZ283148B6 (index.php)
DE (2) DE3588225T2 (index.php)
DK (1) DK171531B1 (index.php)
ES (1) ES8802182A1 (index.php)
FI (1) FI93025C (index.php)
GR (1) GR851317B (index.php)
HU (1) HU204085B (index.php)
IE (1) IE63487B1 (index.php)
IL (1) IL75318A (index.php)
NO (1) NO179075C (index.php)
NZ (1) NZ212207A (index.php)
PL (1) PL155410B1 (index.php)
PT (1) PT80573B (index.php)
RO (1) RO100383A2 (index.php)
SK (1) SK278333B6 (index.php)
YU (1) YU47735B (index.php)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU45104B (en) 1980-04-03 1992-03-10 Biogen Nv Process for producing recombinant dnk molecule, capable of inducting polypeptide expression in an one-cell host
NZ212207A (en) 1984-05-31 1991-07-26 Genentech Inc Recombinant lymphotoxin
US5683688A (en) * 1984-05-31 1997-11-04 Genentech, Inc. Unglycosylated recombinant human lymphotoxin polypeptides and compositions
IL73883A (en) * 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
WO1986003751A2 (en) * 1984-12-21 1986-07-03 Biogen N.V. Purification, production and use of tumor necrosis factors
JPS62111928A (ja) * 1985-10-15 1987-05-22 Kanegafuchi Chem Ind Co Ltd 新規リンホトキシン
AU603768B2 (en) * 1985-07-04 1990-11-29 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Lymphotoxin dna, lymphotoxin expression vector, lymphotoxin resistant cell, transformant with lymphotoxin expression vector and process for preparing lymphotoxin
JPS62195285A (ja) * 1986-02-19 1987-08-28 Kanegafuchi Chem Ind Co Ltd リンホトキシン発現ベクタ−及びそれを用いるリンホトキシンの製造方法
DE3686148T2 (de) * 1985-12-24 1993-01-14 Denki Kagaku Kogyo Kk Lymphotoxin-gen, verfahren zu dessen herstellung und lymphotoxin.
US5403725A (en) * 1985-12-24 1995-04-04 Denki Kagaku Kogyo Kabushiki Kaisha Method for production of lymphotoxin (TNFB) in cell line A-C5-8
JP2548204B2 (ja) * 1987-06-27 1996-10-30 電気化学工業株式会社 新生理活性ポリペプチド
EP0230574A3 (en) * 1986-01-31 1989-03-22 Yale University Pharmaceutical compositions against infections caused by lav/htlv iii virus and the use thereof
JPS62181298A (ja) * 1986-02-05 1987-08-08 Kyowa Hakko Kogyo Co Ltd ヒトリンホトキシンポリペプチド誘導体
DE3620656A1 (de) * 1986-06-20 1987-12-23 Basf Ag Polypeptide mit lymphotoxin-aktivitaet oder lymphotoxin-aehnlicher aktivitaet, ihre herstellung und verwendung
JPS63105680A (ja) * 1986-10-22 1988-05-10 Kanegafuchi Chem Ind Co Ltd ヒト・リンホトキシン発現ベクタ−、該発現ベクタ−による形質転換細胞および該細胞を用いるリンホトキシンの製造方法
JP2636862B2 (ja) * 1986-12-24 1997-07-30 武田薬品工業株式会社 組み換え型ヒトリンホトキシン
US5175268A (en) * 1986-12-24 1992-12-29 Takeda Chemical Industries, Ltd. DNA encoding recombinant human lymphotoxin
FI884798A7 (fi) * 1987-10-28 1989-04-29 Eisai Co Ltd Rekombinantlymfotoxin.
DE3837012A1 (de) * 1988-01-15 1989-07-27 Knoll Ag Verwendung von tnf und lt zur herstellung von arzneimitteln
GB2217326B (en) * 1988-04-08 1991-11-20 British Bio Technology Synthetic gene encoding human tumour necrosis factor beta.
EP0338497A3 (en) * 1988-04-22 1990-05-16 Takeda Chemical Industries, Ltd. Bispecific hybrid monoclonal antibody
JPH023698A (ja) * 1988-06-20 1990-01-09 Denki Kagaku Kogyo Kk ヒトリンホトキシンに対するモノクローナル抗体及びそれら抗体を産生するハイブリドーマ、並びにそれら抗体を用いたヒトリンホトキシンの精製方法、測定方法及び測定試薬
CA2001756A1 (en) * 1988-10-31 1991-04-30 Seiichi Uesugi New human lymphotoxin n-end deletion mutant
JPH03106821A (ja) * 1989-09-20 1991-05-07 Denki Kagaku Kogyo Kk 抗腫瘍剤
US5200176A (en) * 1989-10-06 1993-04-06 Genentech, Inc. Method for protection of ischemic tissues using tumor nerosis factor
US5370870A (en) * 1989-10-06 1994-12-06 Genentech, Inc. Method for protection against reactive oxygen species
IL97779A (en) * 1990-04-10 2000-01-31 Genentech Inc Compositions for cytoprotection against radiation and chemotherapy injury or risk thereof
US5747023A (en) * 1994-07-01 1998-05-05 Genentech, Inc. Cancer therapy using lymphotoxin
ATE219945T1 (de) * 1995-01-23 2002-07-15 Xenotech Inc Zusammensetzung zur verhinderung von osteolyse und metastasen
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
JP2002508962A (ja) 1998-01-15 2002-03-26 ジェネンテク・インコーポレイテッド Ａｐｏ−２リガンド
AU2003302386B2 (en) * 2002-11-26 2010-04-01 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP5068072B2 (ja) 2003-06-27 2012-11-07 バイオジェン・アイデック・エムエイ・インコーポレイテッド 連結ペプチドを含む改変された結合分子
EP1699486A4 (en) * 2003-12-08 2007-07-18 Centocor Inc ANTI-LYMPHOTOXIN HUMAN ALPHA ANTIBODIES, COMPOSITIONS, METHODS AND USES
CA2560742A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
CL2007002926A1 (es) * 2006-10-12 2008-05-16 Genentech Inc Anticuerpo antilinfotoxina alfa (lt-alfa); composicion con el anticuerpo; hibridoma pta-7538; acido nucleico codificante del anticuerpo; vector y celula huesped que comprenden el acido nucleico; metodo para inhibir la proliferacion celular activada p
EP2311481A3 (en) 2006-10-20 2013-10-16 Biogen Idec MA Inc. Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
EP3134103B1 (en) * 2014-04-25 2020-01-15 Naurex Inc. Stable compositions of neuroactive peptides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU88258I2 (index.php) * 1978-12-22 1994-02-03
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
ZA834976B (en) * 1982-07-30 1984-08-29 Genentech Inc Human lymphotoxin
IE56026B1 (en) * 1982-10-19 1991-03-27 Cetus Corp Cysteine-depleted muteins of biologically active proteins
EP0135797A3 (de) * 1983-08-30 1987-11-11 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Herstellung von Lymphotoxin und von Lymphotoxin-mRNA
DE3331108A1 (de) * 1983-08-30 1985-05-02 Boehringer Ingelheim International GmbH, 6507 Ingelheim Verfahren zur herstellung von lymphotoxin und von lymphotoxin-mrna
NZ212207A (en) 1984-05-31 1991-07-26 Genentech Inc Recombinant lymphotoxin

Also Published As

Publication number Publication date
YU47735B (sh) 1996-01-08
SK393085A3 (en) 1996-11-06
DK241385D0 (da) 1985-05-30
CZ393085A3 (en) 1997-07-16
FI93025C (fi) 1995-02-10
IE63487B1 (en) 1995-05-03
EP0509553B1 (en) 2000-08-09
JPH07250692A (ja) 1995-10-03
ES543695A0 (es) 1988-04-16
PL155410B1 (en) 1991-11-29
IE930589L (en) 1985-11-30
NO179075C (no) 1996-07-31
JP2521703B2 (ja) 1996-08-07
DE3588225D1 (de) 2000-09-14
PL253739A1 (en) 1986-03-11
AU4320385A (en) 1985-12-05
BG60256B1 (bg) 1994-03-24
RO100383A2 (ro) 1991-10-17
CA1340641C (en) 1999-07-13
GR851317B (index.php) 1985-11-25
ATE95243T1 (de) 1993-10-15
NO852173L (no) 1985-12-02
EP0164965A2 (en) 1985-12-18
EP0509553A1 (en) 1992-10-21
PT80573B (pt) 1987-08-19
JPS6156197A (ja) 1986-03-20
ATE195323T1 (de) 2000-08-15
FI93025B (fi) 1994-10-31
DK171531B1 (da) 1996-12-23
CZ283148B6 (cs) 1998-01-14
PT80573A (en) 1985-06-01
HU204085B (en) 1991-11-28
AR245219A1 (es) 1993-12-30
HUT37814A (en) 1986-02-28
DE3587597T2 (de) 1994-06-01
JPH07291995A (ja) 1995-11-07
AU599303B2 (en) 1990-07-19
YU91985A (en) 1988-12-31
DE3588225T2 (de) 2001-04-05
DE3587597D1 (de) 1993-11-04
IL75318A0 (en) 1985-09-29
IE851321L (en) 1985-11-30
ES8802182A1 (es) 1988-04-16
JP2804237B2 (ja) 1998-09-24
EP0164965B1 (en) 1993-09-29
IL75318A (en) 1994-08-26
SK278333B6 (en) 1996-11-06
NZ212207A (en) 1991-07-26
DK241385A (da) 1985-12-01
RO100383B1 (ro) 1991-03-01
NO179075B (no) 1996-04-22
EP0164965A3 (en) 1988-04-06
FI852143L (fi) 1985-12-01
FI852143A0 (fi) 1985-05-29

Similar Documents

Publication Publication Date Title
BG60256B2 (bg) Рекомбинантен метод за получаване на лимфотоксин
JP2614989B2 (ja) 腫瘍壊死因子含有組成物
US4650674A (en) Synergistic cytotoxic composition
US7964712B2 (en) Chimeric nucleic acids encoding polypeptides comprising TNF alpha, CD70 and FAS ligand domains
EP0499161A2 (en) GM-CSF inhibiting antibodies
US5683688A (en) Unglycosylated recombinant human lymphotoxin polypeptides and compositions
US6686455B1 (en) Tumor necrosis factor
DK172382B1 (da) Rekombinante lymphotoxinderivater
NZ226980A (en) Lymphotoxin-neutralising antibody and its use in separating out lymphotoxin from a composition
IL104297A (en) Lymphotoxin Nucleic acid encoding vectors containing the nucleic acid and cells converted by them Methods for obtaining lymphotoxin